<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>14</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Role of IL-18 Gene Promoter Polymorphisms, Serum IL-18 Levels, and Risk of Hepatitis B Virus-related Liver Disease in the Guangxi Zhuang Population: a Retrospective Case-Control Study</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>6019</FirstPage>
			<LastPage>6026</LastPage>
			<ELocationID EIdType="pii">31365</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; The aim of this study was to assess the relationship between IL-18 gene polymorphismsand HBV-related diseases and whether these polymorphisms influence its expression in the Guangxi Zhuangpopulation. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: We enrolled 129 chronic HBV infected (CHB) patients, 86 HBV-related livercirrhosis (LC) patients and 160 healthy controls in our study. Polymerase chain reaction-restriction fragmentlength polymorphism methods were used to detect IL-18 gene -607C/A, -137G/C polymorphisms, and an ELISAkit was employed to determine serum IL-18 levels. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: No correlation was found between the -607C/Apolymorphism and risk of HBV-related disease. For the -137G/C polymorphism, the GC genotype and C allelewere associated with a significantly lower risk of CHB (95%CI: 0.32-0.95, p=0.034 and 95%CI: 0.35-0.91,p=0.018) and HBV-related LC (95%CI: 0.24-0.89, p=0.022 and 95%CI: 0.28-0.90, p=0.021). A similar decreasedrisk was also found with the A-607C-137 haplotype. With respect to IL-18 expression, it was significantly lowerin both patient groups, but no association was noted between the two polymorphisms in the IL-18 gene and itsexpression. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Our study indicated that the -137C allele in the IL-18 gene may be a protective factorfor HBV-related disease, and serum IL-18 level may be inversely associated with CHB and HBV-related LC.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Interleukin-18</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">polymorphism - expression - chronic hepatitis B - Liver cirrhosis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_31365_0cfb7636f9614445d8701140406a562a.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
